Recent Updates — ACXP

The Board of Directors approved an amendment to the Company's Bylaws effective October 29, 2026. The change reduces the quorum required for stockholder meetings from a majority of shares entitled to vote to one-third (33⅓%) of the voting power of outstanding shares present or represented by proxy. This governance adjustment facilitates the transaction of business at shareholder meetings. Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for pain management.